ProteomeTech Launches Animal Allergy Diagnostic Product 'Anitia' in Chinese Market

ProteomeTech, a specialized company in in vitro diagnostic medical devices, announced on the 27th that it has entered the Chinese market for the first time with its flagship animal allergy diagnostic product, ANITIA.

This achievement resulted from participating in Pet Fair Asia 2023, the largest pet exhibition in China, held in Shanghai from August 16 to 20. The company initially signed export contracts with five companies and exported to the Chinese market for the first time. Additionally, it is currently negotiating cooperation plans for market entry with over 20 companies in China through various methods. ProteomeTech plans to export its products to more local clients in the future.

Recently, allergic diseases in companion animals have surged, with an incidence rate of over 30%. ANITIA is the first and only product in Korea to receive government approval. It is the only companion animal allergy diagnostic product in Korea certified as a New Excellent Technology (NET) by the Ministry of Agriculture, Food and Rural Affairs.

Replacing the conventional allergy diagnostic method using skin irritation, ANITIA offers many advantages such as cost-effectiveness, convenience, and speed, enabling testing for a total of 125 different allergies with only a small amount of serum. ANITIA is already exported to 11 countries, including the United States, one of the largest markets in the world.

A ProteomeTech official stated, “The animal allergy diagnostic market is formed separately from the human market, which is our main product line, and it has established itself as a representative item for expanding the company’s global sales.” He added, “We believe that animal allergy diagnostic products, along with human allergy diagnostic products, can generate synergistic sales effects.”

This content was produced with the assistance of AI translation services.